Featured Studies

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is conducting a pilot intervention study for patients diagnosed with idiopathic membranous nephropathy. The purpose of this study is to evaluate the safety and effectiveness of Rituximab plus Cyclosporine in the treatment of membranous nephropathy. There is no cost for study-related medications or tests received.

We are looking for people recently diagnosed with Lyme disease to help us answer important questions about the infection. If you have or had the rash associated with acute Lyme disease (erythema migrans), facial palsy, meningitis, heart block, or arthritis; please consider participating in our study.

Researchers want to see if they can measure the amount of anti-cancer drug, Abemaciclib in a brain tumor and brain fluid after a patient has taken this drug for a few days. These findings can help explain how much drug gets into the brain and how drugs work to shrink high grade gliomas to improve outcomes for these patients.

Researchers at NIH are testing a new therapy in patients diagnosed with colitis due to chronic granulomatous disease (CGD). The research aims to see if restoring the gut microbiome reduces inflammation in the colon.

The National Institutes of Health (NIH) is conducting a research study of the causes and responses to treating multiple sclerosis (MS) and other brain and spine inflammatory conditions. Join this study if you have MS or a related disease. Although the study does not offer treatment options, your participation may help in future discoveries and inspire hope.

Research Study 000444-H investigating how well the following vaccines work in patients with CLL/SLL malignancies: SHINGRIX and influenza vaccine. If you are currently receiving treatment for your CLL/SLL (e.g. ibrutinib, acalabrutinib or venetoclax), you may be able to participate.

People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. The risks increase for heart attacks or stroke. No medications have been effective at reducing this risk in people with lupus. Researchers at NIH are testing whether a drug (anifrolumab) can improve blood vessel function and reduce blood vessel inflammation in people with (SLE). Participants do not pay for tests, treatments, or procedures.